ERYCETTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ERYCETTE (ERYCETTE).
Erythromycin is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. This action is bacteriostatic or bactericidal depending on concentration and organism.
| Metabolism | Erythromycin is metabolized primarily in the liver via demethylation by CYP3A4. It is a substrate and inhibitor of CYP3A4. |
| Excretion | Primarily hepatic metabolism; <5% excreted unchanged in urine; ~20% excreted in feces via bile. |
| Half-life | Approximately 1.5–2 hours; prolonged in hepatic impairment. |
| Protein binding | Erythromycin base: 70–90% bound to serum proteins, primarily alpha-1-acid glycoprotein. |
| Volume of Distribution | Not well defined for topical use; systemic absorption negligible; IV Vd: 0.6–0.9 L/kg indicating extensive tissue distribution. |
| Bioavailability | Topical: minimal systemic absorption (<0.1%); oral base: 35%; estolate: variable (can be higher). |
| Onset of Action | Topical: therapeutic effect seen within 2–3 weeks of regular application. |
| Duration of Action | Sustained antibacterial effect on skin; applied twice daily; no systemic duration applicable. |
Apply topically twice daily to affected areas.
| Dosage form | SWAB |
| Renal impairment | No dose adjustment required; renal excretion is minimal. |
| Liver impairment | No dose adjustment required; hepatic metabolism is minimal. |
| Pediatric use | Not recommended for children under 12 years of age. |
| Geriatric use | Use with caution; no specific dose adjustment recommended. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ERYCETTE (ERYCETTE).
| Breastfeeding | Minimal systemic absorption from topical application results in negligible excretion into breast milk. M/P ratio not calculable due to low systemic levels. Compatible with breastfeeding; avoid application directly to the nipple area. |
| Teratogenic Risk | Topical erythromycin (ERYCETTE) has minimal systemic absorption; however, based on oral erythromycin use, there is no evidence of teratogenicity in humans. First trimester: No increased risk of major malformations reported. Second and third trimesters: No specific fetal risks identified. Use is generally considered safe during pregnancy. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to erythromycin or any macrolide antibiotic","Concomitant use with cisapride, pimozide, ergotamine, or dihydroergotamine due to risk of serious cardiac arrhythmias"]
| Precautions | ["May cause QT prolongation and serious cardiac arrhythmias, especially in patients with pre-existing QT prolongation, electrolyte disturbances, or concomitant use of other QT-prolonging drugs","Potential for Clostridioides difficile-associated diarrhea (CDAD)","May exacerbate myasthenia gravis","Hepatic dysfunction, including jaundice and hepatitis"] |
Loading safety data…
| Fetal Monitoring | No specific monitoring required due to minimal systemic exposure. Routine prenatal care is sufficient. |
| Fertility Effects | No known adverse effects on fertility from topical erythromycin. No studies indicate impaired reproductive function. |